Matthew R Sydes
Matthew R Sydes
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College
Verified email at - Homepage
Cited by
Cited by
Practical methods for incorporating summary time-to-event data into meta-analysis
JF Tierney, LA Stewart, D Ghersi, S Burdett, MR Sydes
Trials 8, 1-16, 2007
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial
A Cuschieri, S Weeden, J Fielding, J Bancewicz, J Craven, V Joypaul, ...
British journal of cancer 79 (9), 1522-1530, 1999
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study
GC Barnett, CE Coles, RM Elliott, C Baynes, C Luccarini, D Conroy, ...
The lancet oncology 13 (1), 65-77, 2012
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
DP Dearnaley, MR Sydes, JD Graham, EG Aird, D Bottomley, RA Cowan, ...
The lancet oncology 8 (6), 475-487, 2007
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
P Warde, M Mason, K Ding, P Kirkbride, M Brundage, R Cowan, ...
The Lancet 378 (9809), 2104-2111, 2011
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial
HC Schouten, W Qian, S Kvaloy, A Porcellini, H Hagberg, HE Johnsen, ...
Journal of clinical oncology 21 (21), 3918-3927, 2003
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16, 1-15, 2018
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
DP Dearnaley, G Jovic, I Syndikus, V Khoo, RA Cowan, JD Graham, ...
The lancet oncology 15 (4), 464-473, 2014
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019)
ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ...
European urology 67 (6), 1028-1038, 2015
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label …
NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ...
The Lancet Oncology 17 (10), 1396-1408, 2016
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ...
European journal of cancer 109, 36-50, 2019
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of …
CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ...
The lancet oncology 17 (2), 243-256, 2016
Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial
JT Powell, POBBLE Trial Investigators
Journal of Vascular Surgery 41 (4), 602-609, 2005
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma …
IJ Lewis, MA Nooij, J Whelan, MR Sydes, R Grimer, PCW Hogendoorn, ...
Journal of the National Cancer Institute 99 (2), 112-128, 2007
Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer
W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ...
Journal of Clinical Oncology 35 (27), 3097-3104, 2017
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study
GM Mead, MR Sydes, J Walewski, A Grigg, CS Hatton, P Norbert, ...
Annals of Oncology 13 (8), 1264-1274, 2002
The system can't perform the operation now. Try again later.
Articles 1–20